Affordable Access

deepdyve-link
Publisher Website

Ragweed sublingual tablet immunotherapy: part I - evidence-based clinical efficacy and safety.

Authors
  • Creticos, Peter Socrates1, 2
  • Pfaar, Oliver3, 4
  • 1 Division of Allergy & Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.
  • 2 Creticos Research Group, Crownsville, MD 21032, USA.
  • 3 Department of Otorhinolaryngology, Head & Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. , (Germany)
  • 4 Center for Rhinology & Allergology Wiesbaden, Wiesbaden, Germany. , (Germany)
Type
Published Article
Journal
Immunotherapy
Publisher
Future Medicine
Publication Date
Jun 01, 2018
Volume
10
Issue
7
Pages
605–616
Identifiers
DOI: 10.2217/imt-2017-0186
PMID: 29634392
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.

Report this publication

Statistics

Seen <100 times